LUZHU BIOTECH-B (02480.HK): Phase III Results of Shingles Vaccine LZ901 Published in Nature Communications, Overall Vaccine Efficacy of 91.6%
NewTimeSpace News: Beijing Luzhu Biotechnology Co., Ltd. (stock code: 02480) announced on August 9 that the results of the Phase III clinical trial of the Group's core product LZ901 conducted in China were published in Nature Communications on August 7, 2026. The study was a multicenter, randomized, double-blind, placebo-controlled trial evaluating the protective efficacy and safety of LZ901 in preventing herpes zoster in adults aged 40 and above, enrolling 26,039 subjects, of whom 25,577 received two doses of LZ901 or placebo 30 days apart.
Within one year after vaccination, the overall vaccine efficacy was 91.6% (95% CI: 86.3%–95.3%), with efficacy against laboratory-confirmed cases of 92.1% (95% CI: 86.7%–95.7%), against postherpetic neuralgia (PHN) of 95.9% (95% CI: 63.9%–99.9%), and against severe acute pain associated with herpes zoster of 92.6% (95% CI: 87.2%–96.1%). In terms of safety, within 30 days after vaccination, 16.4% (2,137/13,011) of subjects in the LZ901 group reported at least one adverse reaction, compared with 9.0% (1,167/13,008) in the placebo group (p<0.001); the incidence of Grade 3 adverse reactions showed no significant difference between the two groups (0.4% versus 0.3%, p=0.672).
LZ901 is the Group's self-developed recombinant shingles vaccine, designed to prevent herpes zoster and related complications in adults aged 40 and above. The Company submitted a biologics license application (BLA) for LZ901 to the National Medical Products Administration (NMPA) in January 2025, which was accepted in February 2025 and is currently under review. The Company cautioned that there is no guarantee that LZ901 will ultimately be successfully developed and marketed, and reminded shareholders and potential investors to exercise caution when dealing in the Company's shares.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
